Metraipolis › archive › dc_65e5471f2152
Identification of predictive biomarkers and dose optimization for camrelizumab combined with apatinib in the treatment of advanced hepatocellular carcinoma: a… — Europe PMC PMID:41782865
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41782865
- DOI
- 10.3389/fimmu.2026.1617227
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-05T17:19:15.968Z
- SHA-256 of the archived text
3df09a0ff75070c8db0ffae57c5cc47817871dcd5e2e091423fb1e4d9b791d85- Stable URL of this page
https://metraipolis.com/documento/dc_65e5471f2152
How to cite
Identification of predictive biomarkers and dose optimization for camrelizumab combined with apatinib in the treatment of advanced hepatocellular carcinoma: a… — Europe PMC PMID:41782865 — Europe PMC (en), https://europepmc.org/article/MED/41782865 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_65e5471f2152 (Metraipolis archive dc_65e5471f2152, sha256 3df09a0ff75070c8db0ffae57c5cc47817871dcd5e2e091423fb1e4d9b791d85)
BibTeX
@misc{dc65e5471f2152,
title = {Identification of predictive biomarkers and dose optimization for camrelizumab combined with apatinib in the treatment of advanced hepatocellular carcinoma: a… — Europe PMC PMID:41782865},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41782865},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_65e5471f2152; sha256 3df09a0ff75070c8db0ffae57c5cc47817871dcd5e2e091423fb1e4d9b791d85},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41782865. Agents can read the archived copy with the MCP tool read_document.